The post AAVE Technical Analysis Mar 23 appeared on BitcoinEthereumNews.com. AAVE is stabilizing at the $106.91 level within the general downtrend; it remains belowThe post AAVE Technical Analysis Mar 23 appeared on BitcoinEthereumNews.com. AAVE is stabilizing at the $106.91 level within the general downtrend; it remains below

AAVE Technical Analysis Mar 23

2026/03/23 09:57
5 min di lettura
Per feedback o dubbi su questo contenuto, contattateci all'indirizzo crypto.news@mexc.com.

AAVE is stabilizing at the $106.91 level within the general downtrend; it remains below the EMA20 and momentum indicators are giving bearish signals. Critical support at $106.41 is being tested, a breakdown could lead to movement towards $101, while upwards requires surpassing the $115 resistance.

Executive Summary

AAVE exhibits a clear downtrend structure, trading below the EMA20 at $112.52 with bearish Supertrend signaling resistance at $127.05. Momentum indicators like RSI at 41.26 and negative MACD histogram reinforce selling pressure, while key supports around $106.41 and $100.97 hold near-term downside risks. Multi-timeframe analysis reveals balanced but bearish-leaning levels, with BTC’s downtrend amplifying caution for altcoin exposure. Risk-reward favors shorts above $115 resistance failure, targeting $63.45 downside.

Market Structure and Trend Status

Current Trend Analysis

AAVE’s technical chart reflects a clear downtrend. The price retreated to $106.91 with a 1.45% decline over the last 24 hours, and while the daily range was $104.99-$110.18, the overall structure is characterized by a decline from highs. The Supertrend indicator is giving a bearish signal and marking the $127.05 level as resistance. Short-term trend is bearish, and in the medium term, recovery remains weak without a close above EMA20 ($112.52). On the long-term weekly chart, movement continues within the down channel, with nearly 30% loss from recent peaks observed.

Structural Levels

Structural levels are determined using Fibonacci retracements, pivot points, and historical swing lows/highs. The main downtrend line is flattening around $125, and price holding below it remains bearish in the big picture. Across 1D/3D/1W timeframes, 12 strong levels have been identified: 3 supports/3 resistances on 1D, 1S/1R on 3D, 2S/4R distribution on 1W. This balance indicates a market prone to volatility; rapid movement is expected in the direction of the breakout.

Technical Indicators Report

Momentum Indicators

RSI(14) at 41.26, near oversold but remaining below 50 confirms bearish momentum. In recent days, it has declined from the 60s without showing negative divergence, meaning selling pressure is solid. MACD histogram is negative and below the signal line, with a bearish crossover. Stochastic %K around 35, death cross with %D; for momentum recovery, conditions of RSI above 50 and MACD zero line crossover are needed. Overall confluence is bearish, no buy signals.

Trend Indicators

EMA clustering is bearish: Price below EMA20 ($112.52), EMA50 ($118.45 estimated), and EMA200 (around $135). Closes below EMA20 sustain the trend continuation. Supertrend is bearish, flip requires close above $115. In Ichimoku cloud, price is below the cloud, Tenkan-Kijun death cross active. Bollinger Bands are contracting, squeeze before volatility explosion; lower band near $105 provides support. All trend indicators are accelerating downwards.

Critical Support and Resistance Analysis

Support zones: $92.25 (67/100 score, strong weekly swing low), $106.41 (63/100, daily pivot), $100.97 (62/100, Fibonacci 0.618). Current price at $106.91 is clinging to $106.41 support; if it holds, rebound to $115 possible. Resistance zones: $115.03 (69/100, strongest, near EMA20), $125.00 (60/100, psychological/round), $157.68 (62/100, long-term target). These levels gain strength from multi-TF confluence; $115 breakout opens $145.19 bull target (26 score), below it $63.45 bear target (22 score) appears. Volume-confirmed breakouts are critical.

Volume and Market Participation

24h volume $123.38M, medium level compared to previous days (estimated 10-15% decline), downtrend confirmed with accompanying volume. OBV (On-Balance Volume) showing negative divergence, buying participation weak. VWAP daily around $107.50, price below it means institutions are selling. Buy/Sell volume ratio 0.85 (selling dominant), whale flows net outflow on spot. Volume profile POC (Point of Control) at $105-$110, holding possible in this range but low-volume rallies unreliable. For upward movement, volume increase of 50% required.

Risk Assessment

Risk/reward ratio in bearish scenario 1:2.5 (long: stop below $105, target $145 RR 1:3.5 but low probability; short: entry on $115 rejection, stop $118, target $101 RR 1:4). Main risks: rapid drop to $92 in BTC decline due to altcoin beta effect, volatility spike (5+% daily). Positive risk: unexpected news $115 breakout, but momentum doesn’t support. Overall risk score 7/10 bearish, max 2-3% portfolio exposure, stop-loss mandatory. Volatility 35% (30-day), position size should be adjusted accordingly.

Bitcoin Correlation

AAVE has 0.85+ correlation with BTC; BTC in downtrend at $68,082, Supertrend bearish. BTC supports $67,866 / $64,401 / $62,910 breakdown would push AAVE below $100. Resistance $68,208 / $70,640 breakout would trigger altcoin rally, opening $115 AAVE target. BTC dominance rising, altcoin caution; AAVE shorts preferred until BTC stabilizes. For detailed view, AAVE Spot Analysis and AAVE Futures Analysis.

Conclusion and Strategic Outlook

AAVE’s technical chart is full of bearish confluence: downtrend, price below EMA, negative RSI/MACD, volume supporting selling. Short-term, if $106.41 holds, $115 test; if not broken, $101/$92 targets realistic. Long-term down channel continues, $63 bear final possible. Strategy: short bias, $115 rejection for long/short flip. Aggressive sell if BTC drops below $68k. This comprehensive analysis provides full market view with multi-TF and indicator synthesis; news flow should be monitored. Risk management is essential before investing.

This analysis uses the market views and methodology of Chief Analyst Devrim Cacal.

Strategy Analyst: David Kim

Macro market analysis and portfolio management

This analysis is not investment advice. Do your own research.

Source: https://en.coinotag.com/analysis/aave-comprehensive-technical-analysis-detailed-review-of-march-23-2026

Opportunità di mercato
Logo AaveToken
Valore AaveToken (AAVE)
$105.31
$105.31$105.31
-1.94%
USD
Grafico dei prezzi in tempo reale di AaveToken (AAVE)
Disclaimer: gli articoli ripubblicati su questo sito provengono da piattaforme pubbliche e sono forniti esclusivamente a scopo informativo. Non riflettono necessariamente le opinioni di MEXC. Tutti i diritti rimangono agli autori originali. Se ritieni che un contenuto violi i diritti di terze parti, contatta crypto.news@mexc.com per la rimozione. MEXC non fornisce alcuna garanzia in merito all'accuratezza, completezza o tempestività del contenuto e non è responsabile per eventuali azioni intraprese sulla base delle informazioni fornite. Il contenuto non costituisce consulenza finanziaria, legale o professionale di altro tipo, né deve essere considerato una raccomandazione o un'approvazione da parte di MEXC.

Potrebbe anche piacerti

Supported by hike speculation and PMIs – Danske Bank

Supported by hike speculation and PMIs – Danske Bank

The post Supported by hike speculation and PMIs – Danske Bank appeared on BitcoinEthereumNews.com. Danske Research Team points out that the Euro was the second-
Condividi
BitcoinEthereumNews2026/03/23 15:59
The geopolitics of anti-corruption as global advisory firms face debarment in the Horn of Africa

The geopolitics of anti-corruption as global advisory firms face debarment in the Horn of Africa

The World Bank’s debarment of PwC and EY for fraud in Ethiopia and Somalia has lifted the veil on the fragility of the Western development model, creating a strategic
Condividi
Theexchange2026/03/23 16:33
Health Insurers To Cover Covid Vaccines Despite RFK, Jr. Moves

Health Insurers To Cover Covid Vaccines Despite RFK, Jr. Moves

The post Health Insurers To Cover Covid Vaccines Despite RFK, Jr. Moves appeared on BitcoinEthereumNews.com. The nation’s biggest health insurance companies will continue to cover vaccinations – including those against Covid-19 and seasonal flu – previously recommended by a federal advisory committee, America’s Health Insurance Plans said Wednesday, Sept. 17, 2025. In this photo is a free flu and Covid-19 vaccine shots available sign, CVS, Queens, New York. (Photo by: Lindsey Nicholson/Universal Images Group via Getty Images) UCG/Universal Images Group via Getty Images The nation’s biggest health insurance companies will continue to cover vaccinations – including those against Covid-19 and seasonal flu – previously recommended by a federal advisory committee. The announcement by America’s Health Insurance Plans (AHIP), which includes CVS Health’s Aetna, Humana, Cigna, Centene and an array of Blue Cross and Blue Shield plans as members, comes ahead of the first meeting of the reconstituted Advisory Committee on Immunization Practices, which now has new members chosen by U.S. Health and Human Services Secretary Robert F. Kennedy Jr., a vaccine critic. “Health plans are committed to maintaining and ensuring affordable access to vaccines,” AHIP said in a statement Wednesday. “Health plan coverage decisions for immunizations are grounded in each plan’s ongoing, rigorous review of scientific and clinical evidence, and continual evaluation of multiple sources of data.” The move by AHIP is good news for millions of Americans at a time of year when they flock to drugstores, pharmacies, physician’s offices and outpatient clinics to get their seasonal flu and Covid shots. Kennedy’s changes to U.S. vaccine policy have created confusion across the country over whether certain vaccines long covered by insurance would continue to be. AHIP has now provided some clarity for millions of Americans. “Health plans will continue to cover all ACIP-recommended immunizations that were recommended as of September 1, 2025, including updated formulations of the COVID-19 and influenza vaccines, with no cost-sharing…
Condividi
BitcoinEthereumNews2025/09/18 03:11